$TLSA News

BTIG Initiates Coverage On Tiziana Life Sciences with Buy Rating, Announces Price Target of $7

Tiziana Life Sciences to present Phase 2a BANYAN trial data at ALS Nexus 2026

Tiziana Life Sciences Announces Poster Presentation on Phase 2a BANYAN Clinical Trial of Intranasal Foralumab at ALS Nexus 2026

Tiziana Life Sciences To Present Poster, Titled Phase 2a Trial Of Intranasal Foralumab – BANYAN, A Healey ALS MyMatch Trial, At ALS Nexus 2026

Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer

Tiziana Life Sciences Says Imaging Results Show Neuroinflammation Reduction in Rare Neurodegenerative Condition

Tiziana Life Sciences reports reductions in brain inflammation in third MSA patient

Tiziana Reports Reduction in Brain Inflammation in Third Multiple System Atrophy Patient Treated with Intranasal Foralumab

Tiziana Life Sciences Announces Quantitative PET Imaging Results From Third Patient With Multiple System Atrophy In Its Phase 2 Clinical Trial Treated With Intranasal Foralumab To Complete Dosing; Scans Demonstrated Reductions In Inflammatory Activity

Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman

Tiziana Life Sciences doses last patient in Phase 2a multiple sclerosis trial

Tiziana Announces Last Patient Successfully Dosed in its Phase 2 INFORM-MS Trial

Tiziana Announces Last Patient In Ongoing Phase 2a Clinical Trial Receives First Dose Of Intranasal Foralumab For Treatment Of Non-Active Secondary Progressive Multiple Sclerosis; Topline Data Expected In Late Q3/Early Q4 Of 2026

Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman

Tiziana Life Sciences Says Its Executive Chairman And Founder, Gabriele Cerrone, Increases Holdings With Purchase Of 15,000 Common Shares At $1.11 Per Share

Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York

Tiziana Life Sciences advances foralumab program with full Phase 2 enrollment and encouraging expanded access data – ICYMI

Tiziana Life Sciences completes enrollment in Phase 2a multiple sclerosis trial

Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial

Tiziana Life Sciences Completes Enrollment In Phase 2a Trial Of Intranasal Foralumab For Secondary Progressive Multiple Sclerosis, With Topline Data Expected In Q3 2026